AMARIN CORP PLC\UK Deferred State and Local Income Tax Expense (Benefit)
AMARIN CORP PLC\UK (AMRN) reported Deferred State and Local Income Tax Expense (Benefit) of $1.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-03-02
- AMARIN CORP PLC\UK deferred state and local income tax expense (benefit) for fiscal 2025 was $1.39M.
- AMARIN CORP PLC\UK deferred state and local income tax expense (benefit) for fiscal 2024 was -$1.37M.
- AMARIN CORP PLC\UK deferred state and local income tax expense (benefit) for fiscal 2023 was -$934.00K, a 428.87% decline from fiscal 2022.
- AMARIN CORP PLC\UK deferred state and local income tax expense (benefit) for fiscal 2022 was $284.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.39M 10-K · filed 2026-03-02 | |
| 2024-12-31 | -$1.37M 10-K · filed 2026-03-02 | |
| 2023-12-31 | -$934.00K 10-K · filed 2026-03-02 | |
| 2022-12-31 | $284.00K 10-K · filed 2025-03-12 | -$284.00K 10-K · filed 2023-03-01 |
| 2021-12-31 | -$3.06M 10-K · filed 2024-02-29 | |
| 2020-12-31 | $1.96M 10-K · filed 2023-03-01 | |
| 2019-12-31 | -$914.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | -$1.32M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$487.00K 10-K · filed 2020-02-25 | |
| 2016-12-31 | -$334.00K 10-K · filed 2019-02-27 | |
| 2015-12-31 | -$605.00K 10-K · filed 2018-02-27 | |
| 2014-12-31 | -$226.00K 10-K · filed 2017-03-01 | |
| 2013-12-31 | $631.00K 10-K · filed 2016-02-25 | |
| 2012-12-31 | -$911.00K 10-K · filed 2015-03-03 | |
| 2011-12-31 | -$557.00K 10-K · filed 2014-02-27 | |
| 2010-12-31 | -$87.00K 10-K · filed 2013-02-28 | |
| 2009-12-31 | -$336.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |